BRPI0919199A2 - suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas - Google Patents

suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas

Info

Publication number
BRPI0919199A2
BRPI0919199A2 BRPI0919199A BRPI0919199A BRPI0919199A2 BR PI0919199 A2 BRPI0919199 A2 BR PI0919199A2 BR PI0919199 A BRPI0919199 A BR PI0919199A BR PI0919199 A BRPI0919199 A BR PI0919199A BR PI0919199 A2 BRPI0919199 A2 BR PI0919199A2
Authority
BR
Brazil
Prior art keywords
methods
preparing same
pharmaceutical suspensions
stabilized submicron
submicron
Prior art date
Application number
BRPI0919199A
Other languages
English (en)
Inventor
Bahram Asgharian
Ernesto J Castillo
Masood A Chowhan
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41353867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919199(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of BRPI0919199A2 publication Critical patent/BRPI0919199A2/pt
Publication of BRPI0919199B1 publication Critical patent/BRPI0919199B1/pt
Publication of BRPI0919199B8 publication Critical patent/BRPI0919199B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0919199A 2008-09-19 2009-09-16 suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação BRPI0919199B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9828008P 2008-09-19 2008-09-19
US61/098,280 2008-09-19
PCT/US2009/057065 WO2010033528A1 (en) 2008-09-19 2009-09-16 Stabilized pharmaceutical sub-micron suspensions and methods of forming same

Publications (3)

Publication Number Publication Date
BRPI0919199A2 true BRPI0919199A2 (pt) 2015-12-15
BRPI0919199B1 BRPI0919199B1 (pt) 2020-10-27
BRPI0919199B8 BRPI0919199B8 (pt) 2021-05-25

Family

ID=41353867

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919199A BRPI0919199B8 (pt) 2008-09-19 2009-09-16 suspensão farmacêutica submicrométrica aquosa oftálmica, e seu método de formação

Country Status (26)

Country Link
US (3) US20100076045A1 (pt)
EP (2) EP2425815B1 (pt)
JP (3) JP5739809B2 (pt)
KR (1) KR101682924B1 (pt)
CN (2) CN104688682A (pt)
AR (2) AR073597A1 (pt)
AU (1) AU2009293400B2 (pt)
BR (1) BRPI0919199B8 (pt)
CA (1) CA2736106C (pt)
CL (1) CL2009001856A1 (pt)
CY (1) CY1119740T1 (pt)
DK (1) DK2425815T3 (pt)
ES (2) ES2592503T3 (pt)
HR (1) HRP20180050T1 (pt)
HU (1) HUE037933T2 (pt)
LT (1) LT2425815T (pt)
MX (1) MX348204B (pt)
NO (1) NO2425815T3 (pt)
PL (2) PL2425815T3 (pt)
PT (2) PT2425815T (pt)
RU (1) RU2521258C2 (pt)
SI (1) SI2425815T1 (pt)
TW (1) TWI580441B (pt)
UY (1) UY32095A (pt)
WO (1) WO2010033528A1 (pt)
ZA (1) ZA201101398B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
EP2389355A1 (en) * 2009-03-12 2011-11-30 Medichem, S.A. New crystals of a benzoylbenzeneacetamide derivative
WO2012051575A2 (en) 2010-10-15 2012-04-19 Iscience Interventional Corporation Device for ocular access
ES2597038T3 (es) * 2010-12-06 2017-01-13 Degama Berrier Ltd. Composición y método para mejorar la estabilidad y extender la vida útil de bacterias probióticas y productos alimenticios de las mismas
KR20150006869A (ko) * 2012-05-03 2015-01-19 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
ES3055223T3 (en) 2012-05-03 2026-02-10 Alcon Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
AU2013361292A1 (en) * 2012-12-19 2015-07-09 Kashiv Pharma, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
BR112015020139A2 (pt) 2013-02-20 2017-07-18 Kala Pharmaceuticals Inc compostos terapêuticos e usos dos mesmos
KR102282973B1 (ko) 2013-05-03 2021-07-27 클리어사이드 바이오메디컬, 인코포레이드 안구용 주사를 위한 장치 및 방법
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2016036588A1 (en) * 2014-09-03 2016-03-10 Merck Sharp & Dohme Corp. Pharmaceutical suspensions containing etoricoxib
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US20190216824A1 (en) * 2016-09-16 2019-07-18 Kala Pharmaceuticals, Inc. Particles, Compositions and Methods for Ophthalmic and/or Other Applications
KR20220019667A (ko) * 2019-04-16 2022-02-17 클리어사이드 바이오메디컬, 인코포레이드 주사 가능한 트리암시놀론 제형
WO2025183017A1 (ja) * 2024-02-26 2025-09-04 大塚製薬株式会社 Ｑｕａｂｏｄｅｐｉｓｔａｔ含有組成物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
WO1995005803A1 (en) * 1993-08-20 1995-03-02 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
AU5967101A (en) * 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
RU2219910C2 (ru) * 2002-01-08 2003-12-27 Институт органической и физической химии им. А.Е.Арбузова КНЦ РАН Ветеринарный имплантируемый препарат иммуностимулирующего действия (варианты)
US7138468B2 (en) * 2002-03-27 2006-11-21 University Of Southern Mississippi Preparation of transition metal nanoparticles and surfaces modified with (CO)polymers synthesized by RAFT
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
WO2004064808A1 (en) * 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
RU2006113593A (ru) * 2003-09-23 2006-08-27 Алькон, Инк. (Ch) Препаративные формы триамцинолона ацетонида и анекортава ацетата для инъекций
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
WO2006043172A1 (en) * 2004-10-19 2006-04-27 Pfizer Inc. Pharmaceutical compositions and methods for sub-tenon delivery
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
WO2006109177A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
JP5112669B2 (ja) * 2005-09-30 2013-01-09 富山化学工業株式会社 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment

Also Published As

Publication number Publication date
JP2015052020A (ja) 2015-03-19
PL2328551T3 (pl) 2017-04-28
US20100076045A1 (en) 2010-03-25
RU2011115211A (ru) 2012-10-27
CA2736106A1 (en) 2010-03-25
EP2328551A1 (en) 2011-06-08
CL2009001856A1 (es) 2010-12-31
HK1152258A1 (zh) 2012-02-24
JP2012503003A (ja) 2012-02-02
SI2425815T1 (en) 2018-02-28
NO2425815T3 (pt) 2018-03-24
BRPI0919199B1 (pt) 2020-10-27
ES2657455T3 (es) 2018-03-05
MX2011002494A (es) 2011-04-07
MX348204B (es) 2017-05-30
CY1119740T1 (el) 2018-09-05
EP2425815B1 (en) 2017-10-25
AU2009293400A1 (en) 2010-03-25
PT2425815T (pt) 2018-01-31
KR101682924B1 (ko) 2016-12-06
CN104688682A (zh) 2015-06-10
TWI580441B (zh) 2017-05-01
LT2425815T (lt) 2018-01-25
BRPI0919199B8 (pt) 2021-05-25
AR073597A1 (es) 2010-11-17
ZA201101398B (en) 2012-04-25
HRP20180050T1 (hr) 2018-02-09
RU2521258C2 (ru) 2014-06-27
US20140294970A1 (en) 2014-10-02
KR20110054055A (ko) 2011-05-24
DK2425815T3 (da) 2018-01-29
PL2425815T3 (pl) 2018-03-30
AR124648A2 (es) 2023-04-19
HUE037933T2 (hu) 2018-09-28
EP2425815A1 (en) 2012-03-07
WO2010033528A1 (en) 2010-03-25
JP2017043637A (ja) 2017-03-02
CN102176898A (zh) 2011-09-07
UY32095A (es) 2010-01-29
JP5739809B2 (ja) 2015-06-24
AU2009293400B2 (en) 2015-05-07
TW201014612A (en) 2010-04-16
CA2736106C (en) 2016-08-16
PT2328551T (pt) 2016-09-22
EP2328551B1 (en) 2016-06-15
ES2592503T3 (es) 2016-11-30
US20170216228A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
BRPI0919199A2 (pt) suspensões farmacêuticas submicrométricas estabilizadas e métodos para preparas as mesmas
BRPI0816513A2 (pt) Composição farmacêutica e método para preparar a suspensão sólida
BR112012002335A2 (pt) pigmento composto e método para preparação do mesmo
IL244231A0 (en) Methods for producing aripiprazole suspension and freeze-dried formulation
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0913710A2 (pt) "artigo e métodos para preparação do artigo"
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
PT2868315T (pt) Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
FI20075399L (fi) Uudet dispersiot ja menetelmä niiden valmistamiseksi
BRPI0908379A2 (pt) sistemas e métodos para obter dentaduras customizadas
BRPI0906804A2 (pt) Método para liofilizar partículas, e, acondicionamento farmacêutico
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
BRPI0917714A2 (pt) método para preparar uma microesfera de liberação prolongada, e, microesfera de liberação prolongada
BRPI1012638A2 (pt) métodos e intermediários para preparar agentes farmacêuticos
BRPI0916787A2 (pt) artigo, e, método para fabricar um artigo
BRPI0815550A2 (pt) Método para estabilizar fenilefrina
HRP20170959T1 (hr) Farmaceutska suspenzija
BRPI0921106A2 (pt) biocombustível e processo para preparação de biocombustível
BRPI0815469A2 (pt) Não-tecido e método para produção do mesmo
BRPI0907247A2 (pt) Métodos para preparar biopterina e para preparar tetraidrobiopterina
BRPI0915492A2 (pt) sistemas e métodos para transferir valores
BRPI0921380A2 (pt) processo para preparar partículas oxidantes, e, partículas oxidantes de tamanho reduzido
FI20075431L (fi) Nanopartikkeleihin perustuvat rakenteet ja menetelmät niiden valmistamiseksi
BRPI0917562A2 (pt) composições farmacêuticas e métodos para estabilizar as mesmas
BR112012009737A2 (pt) formulação herbicida em suspenção concretada e processo para preparação da mesma

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF